NCT06666504Completed
The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx Study
The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab (the TezEx Study): a Retrospective and Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
Tezepelumab is a treatment that is approved by NICE (National Institute for Health and Care Excellence, https://www.nice.org.uk/) for patients with severe asthma, that remains poorly controlled despite high dose inhaled glucocorticosteroid medication. The goal of this observational study is to learn why some patients with severe asthma continue to have asthma flare ups despite being on tezepelumab.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 9 Oct 2024
- Start date
- 11 Dec 2024
- Primary completion date
- 20 Jun 2026
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Diseases
- Asthma
- NCT number
- NCT06666504
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 11 Dec 2024 to the primary completion date, 20 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Maintenance therapy with an antibiotic including azithromycin or doxycycline
Other illness
- Other clinically significant medical disease that is likely, in the opinion of the investigator, to require a change in biologic therapy or impact the ability to participate in the study.
- History of current alcohol, drug, or chemical abuse or past abuse that would impair or risk the subject's full participation in the study, in the opinion of the investigator.
- Other severe eosinophilic lung disease including EGPA, chronic eosinophilic pneumonia and ABPA
Other
- Severe bronchiectasis on CT causing daily sputum production
- Inability to give written informed consent
Who the study is looking for
- Patients who qualify for tezepelumab according to NICE eligibility criteria and yet to begin treatment or those patients within 36 weeks (+/-8 weeks) since their first dose of tezepelumab at the Guy's severe asthma centre.
- Age ≥ 18 and ≤ 80 years at tezepelumab initiation.
- Able and willing to provide written informed consent and to comply with the study protocol, including being able to attend for assessment during a symptomatic deterioration.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guys St Thomas NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.